Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil

Immunological Reviews

Volumn 136, Issue 1, 1993, Pages 5-28

  Allison, Anthony C ^a   Eugui, Elsie M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ESTER; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRODRUG; AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID MOFETIL ESTER; UNCLASSIFIED DRUG;

ANIMAL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; DRUG EFFECT; GRAFT REJECTION; HUMAN; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; REVIEW; B LYMPHOCYTE; DRUG METABOLISM; GASTROINTESTINAL DISEASE; IMMUNOMODULATION; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PURINE SYNTHESIS;

ANIMAL; ANTIBODY FORMATION; ESTERS; GRAFT REJECTION; HUMAN; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MYCOPHENOLIC ACID; PRODRUGS;

EID: 0027786826     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1993.tb00652.x     Document Type: Article

References (69)

1. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS‐61443
2. Immunological observations on patients with the Lesch‐Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation
3. The design and development of an immunosuppressive drug, mycophenolate mofetil
4. The role of de novo purine synthesis in lymphocyte transformation
5. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules
6. Cotransfection of ICAM‐1 and HLA‐DR reconstitutes human antigen‐presenting function in mouse L cells
7. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: a long‐term case‐control follow‐up study
8. Cyclosporine nephrotoxicity
9. Graft coronary disease: the lesions and the patients
10. Brequinar sodium, mycophenolic acid and cyclosporin A inhibit different stages of IL‐4 or IL‐13‐induced IgG4 and IgE prouction in vitro
11. Oxidative metabolism of cyclophophamide: identification of the hepatic monooxygenase catalysts of drug activation
12. Comparison of the effects of mizoribine with those of azathioprine. 6‐mercatopurine and mycophenolic acid on T‐lymphocyte proliferation and purine ribonucleotide metabolism
13. In vitro DNA cross‐linking by cyclophosphamide: comparison of human chronic lymphocytic leukaemia cells with mouse L1210 leukemia and normal bone marrow cells
14. VCAM‐I on activated endothelium interacts with the leukocyte integrin VLA‐4 at a site distinct from the fibronectin binding site
15. The purine path to chemotherapy
16. Lymphocyte‐selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion
17. Lymphocyte‐selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
18. Chronic rejection‐graft arteriosclerosis
19. The late results of renal transplantation and the importance of chronic rejection as a cause of graft loss
20. The inhibition of nucleic add synthesis by mycophenolic acid
21. Maintenance immunosuppression with predinisone and RS‐61443 alone following liver transplantation
22. Increasing methotrexate response with increasing dose in the treatment of resistant rheumatoid arthritis
23. Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes
24. Adenosine deaminase deficiency two patients with severely impaired cellular immunity
25. Efficacy of mycophenolic acid for the treatment of psoriasis
26. Down regulation of cell adhesion molecules LFA‐3 and ICAM‐1 in Epstein‐Barr virus‐positive Burkitt's lymphoma underlies tumor cell escape from virus‐specific T cell surveillance
27. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergaulin on vascular muscle proliferation in vitro and in vivo
28. Epstein‐Barr virus (EBV)‐induced polyclonal B‐cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathological and virologic findings and implications for therapy
29. Tolerance induction in adult mice: cyclosporine inhibits RS‐61443‐induced tolerance
30. RS‐61443 allows islet allografting and specific tolerance induction in adult mice
31. Organ specific activation of azathioprine in mice: role of liver metabolism in mutation induction
32. Inhibition of in vitro vascular endothelia] cell proliferation and in vivo vascularization by low‐dose methotrexate
33. Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation lymphocytes
34. Purine metabolism and control of cell proliferation
35. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM‐1 and LFA‐1
36. The pharmacology and clinical use of methotrexate
37. How one thing has led to another
38. Structure of glycoproteins and their oligosaccharide units
39. Chromosomal translocations in lymphoid malignancies reveal novel proto‐oncogenes
40. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells
41. Selectins: interpreters of cell‐specific carbohydrate information during inflammation
42. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins
43. Bioavailability improvement of mycophenolic acid through amino ester derivitization
44. Treatment of cyclophosphamide‐induced hemorrhagic cystitis with intravesical carboprost tromethamine
45. ELAM‐1 ‐dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA
46. Spectrum of vascular changes in primate cardiac xenografts
47. Immunosuppressive effect of mycophenolic acid
48. Mycophenolic acid morpholinoethylester (RS‐61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis
49. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS‐61443) in rat and nonhuman primate recipients of heart allografts
50. Human type I and II IMPDH as drug targets
51. Heart graft artherosclerosis
52. Tumors of the immunocompromised patient
53. Effects of adenosine and deoxyadenosine on PHA‐stimulation of lymphocytes of man, horse and pig
54. RS‐61443 for reversal of acute rejection in canine renal allografts
55. RS‐61443, a new potent immunosuppressive agent
56. Glycobiology
57. Failure of dideoxynucleosides to inhibit HIV replication in cultured human macrophages
58. T‐cell‐mediated regression of “spontaneous” and Epstein‐Barr virus‐induced B‐cell transformation in vitro: studies with cyclosporin A
59. Cellular basis of skin graft rejection: an in vivo model of immune‐mediated tissue destruction
60. Action of bredinin on mammalian cells
61. 2‐morpholino‐ethyl mycophenolic acid (ME‐MPA) in the treatment of refractory rheumatoid arthritis (RA)
62. RS‐61443 ‐ a phase I clinical trial and pilot rescue study
63. Effects of immunosuppressive therapy in the rat aortic allograft model
64. Biosynthesis of nucleotides
65. Carbohydrate ligands for endothelial‐leukocyte adhesion molecule 1
66. Purification, characterization and kinetic analysis of inosine‐5′‐monophosphate dehydrogenase of Trichomonas foetus
67. Neutrophil influx into an inflammatory site inhibited by a soluble bearing receptor‐Ig chimaera
68. Antipurines and purine metabolism